Law360 (September 19, 2019, 4:19 PM EDT) — When the 2018 Farm Bill removed hemp from the definition of marijuana — and thus from the list of Schedule I drugs under the Controlled Substance Act, or CSA — it unlocked an industry ripe for expansion. Sales of products containing CBD are booming — indeed, analysts predict that CBD sales could become a $15-$20 billion industry by 2025.[1]
However, CBD companies are still faced with a regulatory quagmire, struggling to understand how to legally promote, label and distribute CBD consumables in light of the FDA gridlock, inconsistent state laws and uncertainty as to which pathway will result in a viable…
